Treatment of HUtMEC cells with recombinant s(P)RR (Fig. 1) resulted in increased levels of endothelial dysfunction markers; VCAM-1, ICAM-1, and ET-1, suggesting that elevated s(P)RR has the potential to cause systemic maternal endothelial dysfunction. Here, EDN1 is linked to endothelial dysfunction.